News | Computed Tomography (CT) | May 18, 2021

CT features help select patients with stage IA non-small cell lung cancer for sublobar resection, rather than more extensive surgery

(A) 70-year-old woman with pulmonary adenocarcinoma who underwent sublobar resection without evidence for pLVI. 15-mm solid nodule with irregular margins present in right lower lobe (arrow). No tumor recurrence on 37-month follow-up. (B) 75-year-old man with pulmonary adenocarcinoma who underwent wedge resection that exhibited pLVI. 19-mm solid nodule with irregular margins and peritumoral interstitial thickening (arrowheads) present in right upper lobe. Ipsilateral mediastinal and hilar lymph node metastas

(A) 70-year-old woman with pulmonary adenocarcinoma who underwent sublobar resection without evidence for pLVI. 15-mm solid nodule with irregular margins present in right lower lobe (arrow). No tumor recurrence on 37-month follow-up. (B) 75-year-old man with pulmonary adenocarcinoma who underwent wedge resection that exhibited pLVI. 19-mm solid nodule with irregular margins and peritumoral interstitial thickening (arrowheads) present in right upper lobe. Ipsilateral mediastinal and hilar lymph node metastasis occurred after 5-month follow-up (not shown). Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


May 18, 2021 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), computed tomography (CT) features may help identify which patients with stage IA non-small cell lung cancer are optimal candidates for sublobar resection, rather than more extensive surgery.

This retrospective study included 904 patients (453 men, 451 women; mean age, 62 years) who underwent lobectomy (n=574) or sublobar resection (n=330) for stage IA non-small cell lung cancer. Two thoracic radiologists independently evaluated findings on preoperative chest CT, later resolving any discrepancies. Recurrences were identified via medical record review.

"In patients with stage IA non-small cell lung cancer, pathologic lymphovascular invasion was observed only in solid-dominant part solid nodules and solid nodules with solid portion diameter over 10 mm," concluded corresponding author Mi Young Kim from the department of radiology at the University of Ulsan College of Medicine, Asan Medical Center.

"Among such nodules," the authors of this AJR article continued, "peritumoral interstitial thickening (odds ratio=13.22) and pleural contact (odds ratio=2.45) were independently associated with pathologic lymphovascular invasion." Moreover, models incorporating these features independently predicted recurrence-free survival after sublobar resection (hazard ratio=5.37-6.05).

For more information: www.arrs.org


Related Content

News | RSNA 2025

Nov. 13, 2025 — Nano-X Imaging Ltd., a medical imaging technology company, will showcase its Nanox.ARC X multi-source ...

Time November 25, 2025
arrow
News | Artificial Intelligence

Nov. 24, 2025 — Siemens Healthineers is launching artificial intelligence-enabled services to help healthcare providers ...

Time November 24, 2025
arrow
News | Artificial Intelligence

Nov. 20, 2025 — Aidoc has announced a collaboration with AdventHealth to launch one of the largest imaging AI ...

Time November 21, 2025
arrow
News | Radiology Business

Nov. 13, 2025 — Covera Health recently announced that Advanced Radiology Services (ARS) has joined its national Quality ...

Time November 17, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Orthopedic Imaging

Nov.10, 2025 — Medical imaging technology company Adaptix Ltd. has received 510(k) clearance from the U.S. Food and Drug ...

Time November 11, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Nov. 10, 2025 — There has been substantial progress in the past few years in the field of MRI in general and remote MR ...

Time November 11, 2025
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
Subscribe Now